ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

KNB Kanabo Group Plc

0.90
0.00 (0.00%)
20 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Kanabo Group Plc LSE:KNB London Ordinary Share GB00BYQCS703 ORD 2.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.90 0.80 1.00 0.90 0.839 0.90 600,076 08:00:03
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Medical Laboratories 895k -7.99M -0.0126 -0.71 5.69M

Kanabo Group PLC Contract Extension With Major UK Retailer (2855T)

14/11/2023 7:00am

UK Regulatory


Kanabo (LSE:KNB)
Historical Stock Chart


From Dec 2022 to Dec 2024

Click Here for more Kanabo Charts.

TIDMKNB

RNS Number : 2855T

Kanabo Group PLC

14 November 2023

14 November 2023

Kanabo Group Plc

("Kanabo", the "Group" or the "Company")

Contract Extension With Major UK Retailer

Kanabo Group plc (LSE: KNB), the patient-focused provider of digital health services and specialist medicines, including medicinal cannabis, is pleased to announce that it has extended an existing contract with a leading United Kingdom ("UK") retail business, a provider of health and beauty retail and e-pharmacy services.

The GP Service - acquired by Kanabo in 2022 - originally partnered with the retailer in 2019. The contract extension will see Kanabo, through its integrated online telehealth platform The GP Service, continue to provide the retailer with video consultation and prescription services, which patients can access remotely and then collect through the Group's network of over 4,000 UK pharmacies for a further 12 months.

This contract extension will enable Kanabo to continue to offer its online consultation services to an expanded patient base, affording patients faster and easier access to medical professionals.

Avihu Tamir, Chief Executive Officer of Kanabo, commented:

"I am delighted that we have secured an extension of this prestigious contract for Kanabo. The continuation of our relationship with this retailer will help us strengthen our position as a key player in digital health services and also provide accessible care to patients. We look forward to continuing to work with them over the next 12 months, and to enabling greater access to medical professionals and healthcare services for customers."

Enquiries:

 
  Kanabo Group plc                                         via Vigo Consulting 
   Avihu Tamir, Chief Executive Officer                     +44 (0)20 7390 0230 
   Assaf Vardimon, Chief Financial Officer 
   Ian Mattioli, Non-Executive Chair of the Board 
  Peterhouse Capital Limited (Financial Adviser 
   and Broker) 
   Eran Zucker / Lucy Williams / Charles Goodfellow        +44 (0)20 7469 0930 
  Vigo Consulting (Financial Public Relations/Investor 
   Relations) 
   Jeremy Garcia / Fiona Hetherington / Verity 
   Snow                                                     +44 (0)20 7390 
   kanabo@vigoconsulting.com                                 0230 
 

About Kanabo Group plc

Kanabo Group plc (LSE:KNB) is a digital health company committed to transforming patient care through its innovative technology platform and specialised treatment offerings. Since its inception in 2017, Kanabo has been focused on researching, developing, and commercialising regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.

Kanabo's NHS-approved online telehealth platform, The GP Service, provides patients with video consultations, online prescriptions, and primary care services. Leveraging its telehealth capabilities, in February 2023, Kanabo launched Treat It - an online clinic focused on chronic pain management providing patients with secondary care.

With its two complementary business divisions, Kanabo has established itself as an end-to-end digital health provider, offering telehealth consultations, prescriptions, alongside the delivery of tailored treatments.

The Company's partially owned subsidiary, Kanabo Agritec Ltd, is a cultivation consultancy supporting cannabis businesses in developing new farms through infrastructural, research, and product guidance. These farms deliver high-quality raw materials for Kanabo's formulas and product line.

At Kanabo Group Plc, we are dedicated to providing patients with the highest quality medical treatments and more accessible healthcare experiences.

Visit www.kanabogroup.com for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CNTDZMMMVFZGFZM

(END) Dow Jones Newswires

November 14, 2023 02:00 ET (07:00 GMT)

1 Year Kanabo Chart

1 Year Kanabo Chart

1 Month Kanabo Chart

1 Month Kanabo Chart

Your Recent History

Delayed Upgrade Clock